Psilocybin for Depression Study Approved and Funded by German Government

Psilocybin Alpha reports..

The German Government has approved a Phase 2b study on psilocybin for treatment-resistant depression, and is providing millions of Euros to this latest psychedelic research project.

Germany’s Federal Institute for Drugs and Medical Devices has approved a study on the Efficacy and Safety of Psilocybin in Treatment-Resistant Depression, known by the shorthand ‘EPIsoDE’. This marks the first psilocybin depression study in Germany since the 1970s.

The phase 2b two-centre study will investigate the safety and efficacy of psilocybin in a controlled, randomised double-blind design. Specifically, a therapeutic dose of psilocybin (25mg) will be compared to an active control dose of psilocybin (5mg) and niacin. A second therapeutic dose will be administered six weeks after the first. The study expects to have 144 participants.

Read their full report at.

Primary Sponsor

Karma Koala Podcast

Top Marijuana Blog